REZOLUTE, INC. Form DEF 14A: Definitive proxy statement
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2025-10-07: Form DEF 14A; Period of report 2025-11-19; Description DEF 14A; Document rzlt-20251119xdef14a.htm.
- 2024-10-21: Form DEF 14A; Period of report 2024-12-05; Description DEF 14A; Document tm2425798-2_def14a.htm.
- 2024-04-15: Form DEF 14A; Period of report 2024-05-16; Description DEF 14A; Document tm242983-1_def14a.htm.
- 2023-04-12: Form DEF 14A; Period of report 2023-05-25; Description DEF 14A; Document tm2312168-1_def14a.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2025-10-07 | DEF 14A | 2025-11-19 | DEF 14A | rzlt-20251119xdef14a.htm |
| 2024-10-21 | DEF 14A | 2024-12-05 | DEF 14A | tm2425798-2_def14a.htm |
| 2024-04-15 | DEF 14A | 2024-05-16 | DEF 14A | tm242983-1_def14a.htm |
| 2023-04-12 | DEF 14A | 2023-05-25 | DEF 14A | tm2312168-1_def14a.htm |
| 2022-05-16 | DEF 14A | 2022-06-16 | DEF 14A | tm223666-2_def14a.htm |
| 2021-04-28 | DEF 14A | 2021-05-26 | DEF 14A | tm2112512-2_def14a.htm |
| 2019-09-23 | DEF 14A | 2019-10-23 | DEF 14A | tv529863_def14a.htm |
| 2019-04-05 | DEF 14A | 2019-04-24 | DEF 14A | tv518301_def14a.htm |
| 2017-10-20 | DEF 14A | 2017-11-28 | DEFINITIVE PROXY STATEMENT | tv477059_def14a.htm |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |